For Enquiry : +(91) 9923599971

Dr. Reddy's Laboratories Limited

DATE OPEN HIGH LOW CLOSE VOLUME
19-10-2018 2550.0000 2582.8999 2530.5000 2552.3501 436967
17-10-2018 2580.0000 2599.0000 2552.0000 2565.0000 492009
16-10-2018 2566.8999 2590.0000 2537.5000 2573.6001 600003
15-10-2018 2461.1001 2579.9500 2443.3999 2566.8501 1123276
12-10-2018 2460.0000 2490.9500 2432.4500 2450.5000 925386
11-10-2018 2412.0500 2516.0000 2408.0000 2459.0000 548027
10-10-2018 2465.0000 2514.0500 2456.0000 2484.6001 893571
09-10-2018 2357.6499 2477.0000 2341.9500 2454.1499 1127674
08-10-2018 2395.0000 2407.7500 2332.0000 2340.1001 603789
05-10-2018 2356.0000 2429.1001 2350.3000 2394.5500 736953
04-10-2018 2469.0000 2493.9500 2360.2500 2372.4500 804214
03-10-2018 2517.0000 2549.0000 2482.0000 2489.5500 705888
01-10-2018 2531.0000 2540.7000 2440.3501 2508.6001 762356
28-09-2018 2559.0000 2577.0000 2484.5500 2530.6499 1069703
27-09-2018 2609.8999 2620.3501 2529.0000 2541.0000 1050352
26-09-2018 2617.7000 2664.2000 2591.0000 2600.8501 1206238
25-09-2018 2570.6001 2619.2500 2550.2500 2611.7000 759251
24-09-2018 2577.8000 2600.9500 2529.3000 2553.9500 688659
21-09-2018 2643.9500 2670.8000 2441.1001 2556.2500 1411007
19-09-2018 2603.3999 2636.0000 2571.0000 2607.1001 869947
18-09-2018 2579.8999 2637.0000 2570.0000 2584.1499 1111458
17-09-2018 2581.0000 2615.0000 2547.8999 2568.5000 691773
14-09-2018 2555.8999 2595.0000 2550.0500 2581.8501 677333
12-09-2018 2526.0000 2574.4500 2487.6001 2529.1499 1248825
11-09-2018 2578.4500 2586.4500 2507.1001 2524.4500 1136931
10-09-2018 2623.8000 2659.8000 2555.0000 2563.8999 1323873
07-09-2018 2575.0000 2644.3000 2545.6001 2632.5000 1306632
06-09-2018 2584.0000 2620.0000 2555.1001 2566.9500 1084494
05-09-2018 2549.3000 2590.0000 2518.5000 2567.7000 1127153
04-09-2018 2595.0000 2615.0000 2537.0500 2543.1001 1036459
03-09-2018 2510.0000 2632.0000 2495.0000 2593.3999 3039924
31-08-2018 2397.0000 2499.0000 2395.0000 2492.0000 1981320
30-08-2018 2385.0000 2417.9500 2375.0500 2380.1499 1078598
29-08-2018 2420.0000 2429.5000 2377.5000 2383.8501 638133
28-08-2018 2450.0000 2480.0000 2407.0500 2414.5000 750408
27-08-2018 2453.0000 2462.9500 2426.5000 2443.1001 457122
24-08-2018 2475.0000 2477.3999 2425.6001 2447.4500 576704
23-08-2018 2430.0000 2520.0000 2425.0000 2463.6001 1624568
21-08-2018 2388.0000 2427.8999 2354.1001 2410.9500 638958
20-08-2018 2365.0000 2396.9500 2365.0000 2380.7500 361318
17-08-2018 2373.8999 2411.3000 2350.8999 2364.1499 889022
16-08-2018 2275.3501 2361.4500 2270.8501 2353.4500 895988
14-08-2018 2254.0000 2291.0000 2239.0500 2278.4500 482038
13-08-2018 2220.0000 2249.0000 2215.1499 2241.6001 267323
10-08-2018 2236.3999 2256.8999 2205.5000 2214.3000 323888
09-08-2018 2263.8999 2263.8999 2205.0500 2237.7000 390701
08-08-2018 2263.0000 2280.0000 2237.0000 2245.5000 345399
07-08-2018 2249.8999 2281.4500 2245.0500 2258.8000 499910
06-08-2018 2285.0000 2325.0000 2228.2000 2234.3999 835775
03-08-2018 2236.0000 2290.0000 2230.0000 2281.0500 1013107
02-08-2018 2175.0000 2237.9500 2170.0000 2227.8501 1039641
01-08-2018 2130.0000 2182.0000 2130.0000 2175.7000 912903
31-07-2018 2075.0000 2135.0000 2070.6001 2127.8000 1464380
30-07-2018 2080.0500 2092.8501 2058.3000 2067.2000 807995
27-07-2018 2135.0000 2135.0000 2067.3999 2083.2000 896318
26-07-2018 2075.7000 2191.0000 2074.8999 2132.7500 1913049
25-07-2018 2087.0000 2097.5000 2061.5500 2088.2000 538614
24-07-2018 2043.0000 2090.0000 2043.0000 2077.6001 1289377
23-07-2018 2073.0000 2073.0000 2032.5000 2041.7000 587029
20-07-2018 2026.0000 2073.0000 2020.0000 2051.8999 755783
19-07-2018 2077.8000 2077.8000 2025.0000 2029.2000 762721
18-07-2018 2080.0000 2096.5500 2040.5000 2065.6499 1219549
17-07-2018 2060.0000 2119.0000 2057.0500 2065.3000 1422184
16-07-2018 2223.1001 2223.1001 2069.9500 2093.9500 3721516
13-07-2018 2340.0000 2366.3999 2301.0000 2319.8501 466927
12-07-2018 2326.7000 2387.6499 2326.6499 2357.2500 1312367
11-07-2018 2301.0000 2333.0000 2275.0000 2301.3501 820067
10-07-2018 2345.6001 2345.6001 2303.0000 2321.8501 665940
09-07-2018 2282.0000 2335.0000 2281.9500 2330.0500 729897
06-07-2018 2300.0000 2319.8999 2255.8501 2269.0500 556218
05-07-2018 2329.9500 2348.7000 2287.7500 2298.6499 830939
04-07-2018 2273.8000 2338.0000 2273.8000 2317.2500 1065535
03-07-2018 2258.0000 2284.0000 2235.2000 2273.7500 756573
02-07-2018 2230.0000 2260.5500 2202.2500 2240.3501 774325
29-06-2018 2279.9500 2284.0000 2223.0000 2235.0500 898423
28-06-2018 2289.0000 2325.9500 2272.2000 2295.7500 1228463
27-06-2018 2257.8999 2306.8000 2245.8999 2293.8000 1552070
26-06-2018 2284.0000 2285.0000 2257.3999 2267.1499 628148
25-06-2018 2305.0000 2326.8000 2281.0000 2290.1499 1142767
22-06-2018 2325.0000 2347.5000 2274.0500 2336.2500 1667277
21-06-2018 2389.0000 2389.0000 2306.5000 2316.3999 1115131
20-06-2018 2393.0000 2409.8999 2352.9500 2367.7500 1149681
19-06-2018 2403.2000 2429.6001 2376.5500 2393.0000 2106466
18-06-2018 2339.0000 2411.0000 2292.3999 2385.8501 2310151
15-06-2018 2303.0000 2385.8000 2296.2500 2349.8501 4456911
14-06-2018 2260.0500 2299.6499 2246.5500 2269.3999 1588963
13-06-2018 2190.0000 2304.0000 2185.0000 2256.3000 2580254
12-06-2018 2097.0000 2195.0000 2097.0000 2190.6499 2097114
11-06-2018 2062.0500 2125.0000 2051.6499 2083.2000 1612295
08-06-2018 1973.0000 2072.6001 1973.0000 2062.8999 1113559
07-06-2018 1965.0000 1976.9500 1961.2000 1964.9500 152700
06-06-2018 1963.0000 1977.9000 1948.0000 1960.4500 415605
05-06-2018 1980.0000 1987.5500 1954.0000 1963.4000 365344
04-06-2018 1978.0000 2027.9000 1965.0000 1996.0000 1400421
01-06-2018 1940.0000 1963.4500 1932.3500 1941.4000 441861
31-05-2018 1971.8000 1971.8000 1925.9500 1936.6000 1860178
30-05-2018 1975.0000 1975.0000 1952.0000 1961.8000 335848
29-05-2018 2000.0000 2014.5500 1972.6000 1980.7000 490670
28-05-2018 1966.7500 2012.0500 1960.0000 1994.5500 508364
25-05-2018 1975.0000 1995.8000 1965.0000 1967.8500 435249

DRREDDY NEWS

  • Dr. Reddy's Laboratories Receives Approval For Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

    Dr. Reddy’s Laboratories Ltd Today Announced Receipt Of Approval For Aspirin And Extended-Release Dipyridamole Capsules, A Therapeutic Equivalent Generic Version Of Aggrenox Capsules In The United States Market From The U.S.

  • Dr. Reddy's Laboratories Announces The Sale Of Its API Manufacturing Business Unit In Jeedimetla, Hyderabad

    Dr. Reddy’s Laboratories Ltd. Today Announced That It Has Entered Into A Definitive Agreement For The Sale Of Its API Manufacturing Business Unit Located In Jeedimetla, Hyderabad, To Therapiva Private Ltd., An Emerging Generics Pharmaceutical Company. This Divestiture Is Being Done By Way Of Slump Sale And Includes All Related Fixed Assets , Current Assets, Current Liabilities, And Its Employees.

  • Dr. Reddy's Laboratories Announces The Launch Of Colesevelam Hydrochloride Tablets In The U.S. Market

    Dr. Reddy’s Laboratories Ltd. Today Announced That It Has Launched Colesevelam HCl Tablets, USP, A Therapeutic Equivalent Generic Version Of WELCHOL Tablets In The United States Market Approved By The U.S.

  • Dr. Reddy's To Release Q2 FY19 Results On October 26, 2018

    Earnings Call Slated For October 26, 6:00 PM IST / 8:30 AM EDT

  • Dr. Reddy's Sells Antibiotic Production Hub To UAE Drugmaker

    Dr. Reddy's (RDY) Divests Its Bristol, TN-based Antibiotic Manufacturing Site And Related Assets To An Abu Dhabi-based Company.

  • Dr. Reddy's Laboratories Announces The Sale Of Cloderm® (clocortolone Pivalate) Cream, 0.1% Franchise To EPI Health, LLC

    Dr. Reddy’s Laboratories Ltd. Announced Today That Its Wholly Owned Subsidiary Promius Pharma, LLC, Has Sold Its Rights Of Cloderm® Cream, 0.1% And Its Authorized Generic To EPI Health, LLC, An Affiliate Of EPI Group, LLC.

  • Who Are The Top Investors In Dr Reddy’s Laboratories Limited (NSE:DRREDDY)?

    If You Want To Know Who Really Controls Dr Reddy’s Laboratories Limited (NSE:DRREDDY), Then You’ll Have To Look At The Makeup Of Its Share Registry. Institutions Will Often Hold Stock


  • Dr. Reddy's Laboratories Announces The Launch Of Imatinib Mesylate Tablets, USP In The U.S. Market

    Dr. Reddy’s Laboratories Ltd. Today Announced The Launch Of Imatinib Mesylate Tablets, USP, A Therapeutic Equivalent Generic Version Of Gleevec Tablets In The United States Market Approved By The U.S.

  • Dr. Reddy’s Laboratories Announces That It Has Regained Worldwide Rights To DFA-02

    Dr. Reddy’s Laboratories Ltd. Today Announced The Termination Of The License Granted To Armis Biopharma, Inc.

  • Dr. Reddy's Laboratories Announces The Sale Of Its Antibiotic Manufacturing Site And Its Related Assets In Bristol, Tennessee

    Dr. Reddy’s Laboratories Ltd. Today Announced The Closure Of The Sale Of Its Antibiotic Manufacturing Facility And Related Assets In Bristol, Tennessee To Neopharma Inc., A Wholly Owned Subsidiary Of The UAE’s Largest Pharmaceutical Manufacturer Headquartered In Abu Dhabi.

  • Dr. Reddy's (RDY) Presence In Generics Market Remains Strong

    Dr. Reddy's Has A Strong Hold In The Generics Market. New Product Launches, Especially Complex Generics, Are Likely To Drive The Generics Business At Regular Intervals.

  • Dr. Reddy's Laboratories Announces The Launch Of Neostigmine Methylsulfate Injection, USP In The U.S. Market

    Dr. Reddy’s Laboratories Ltd. Today Announced The Launch Of Neostigmine Methylsulfate Injection, USP, A Therapeutic Equivalent Generic Version Of Bloxiverz Injection Approved By The U.S.

  • The Zacks Analyst Blog Highlights: Dr. Reddy's Laboratories, Infosys, ICICI Bank And HDFC Bank

    The Zacks Analyst Blog Highlights: Dr. Reddy'sLaboratories, Infosys, ICICI Bank And HDFC Bank

  • Dr. Reddy's (RDY) Earnings And Revenues Improve Y/Y In Q1

    Dr Reddy's (RDY) Surpasses Both Earnings And Sales Year Over Year In The First Quarter Of Fiscal 2019.

  • Doctor Reddy's: Fiscal 1Q Earnings Snapshot

    The Hyderabad, India-based Company Said It Had Net Income Of 40 Cents Per Share. The Pharmaceutical Posted Revenue Of $543 Million In The Period. Doctor Reddy's Shares Have Dropped 19 Percent Since The ...

  • Dr. Reddy’s Q1 FY19 Financial Results

    Dr. Reddy’s Laboratories Ltd. Today Announced Its Consolidated Financial Results For The Quarter Ended June 30, 2018 Under International Financial Reporting Standards .

  • Dr.Reddy's Profit Soars On Anti-opioid Drug Sales In U.S.

    Net Profit Came In At 4.76 Billion Rupees ($69.31 Million) In The Quarter Ended June 30, Compared With 666 Million Rupees A Year Earlier, The Company Said. Analysts On Average Had Expected A Net Profit Of 2.98 Billion Rupees, According To Thomson Reuters I/B/E/S. Dr.Reddy's Got Approval To Sell Versions Of Indivior Plc's Best-selling Opioid Addiction Treatment Last Month, Materially Hurting The British Drugmaker's Revenue And Forcing It To Scrap Its Full-year Forecast Amid Market Share Loss.

  • India's Dr.Reddy's Profit Soars On Anti-opioid Drug Sales In U.S.

    Indian Generic Drugmaker Dr.Reddy's Laboratories Ltd Posted An Over Seven-fold Rise In First-quarter Net Profit On Thursday, Handily Beating Market Expectations, Aided By The U.S. Launch Of A Generic Version ...

  • India's Dr. Reddy's Q1 Net Profit Rises Seven-fold, Beats Forecast

    Indian Generic Drugmaker Dr. Reddy's Laboratories Ltd Posted An Over Seven-fold Rise In First-quarter Net Profit On Thursday, Handily Beating Market Expectations, Aided By The Launch Of A Generic Version ...

  • Dr. Reddy's Laboratories Announces The Launch Of Hervycta® (trastuzumab Biosimilar) In India

    Dr. Reddy’s Laboratories Ltd. Announced Today That It Has Launched Hervycta® , A Biosimilar Of Roche’s Herceptin®, In India, Indicated For The Treatment Of HER2-positive Cancers .

Technical Chart

Chat

Sharemarket Tips

Get 2 Rupay

Any Queries

Chat Now
Stock Market Advice

international markets

About us | Contact Us | Feedback | Disclaimer | Privacy Statement | Terms of Use | Financial Terms (Glossary) | FAQs

Copyright © 2018 Get2rupay. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express writtern permission of get2rupay.com is prohibited.